Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025
Daré Bioscience (NASDAQ: DARE), a women's health innovation company, has scheduled its full year 2024 financial results conference call and webcast for March 31, 2025, at 4:30 p.m. Eastern Time. The presentation will include both financial performance review and company updates.
Participants can join via phone at (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free) using conference ID 9767621. A live webcast will be available through the Investors section of Daré's website. The webcast recording will remain accessible for replay until April 14, 2025.
Daré Bioscience (NASDAQ: DARE), un'azienda innovativa nel settore della salute femminile, ha programmato la sua conferenza telefonica e webcast sui risultati finanziari dell'intero anno 2024 per il 31 marzo 2025, alle 16:30 ora orientale. La presentazione includerà sia una revisione delle performance finanziarie che aggiornamenti sull'azienda.
I partecipanti possono unirsi telefonicamente al numero (646) 307-1963 (U.S.) o (800) 715-9871 (numero verde) utilizzando l'ID conferenza 9767621. Un webcast dal vivo sarà disponibile nella sezione Investitori del sito web di Daré. La registrazione del webcast rimarrà accessibile per il replay fino al 14 aprile 2025.
Daré Bioscience (NASDAQ: DARE), una empresa de innovación en salud femenina, ha programado su llamada de conferencia y webcast sobre los resultados financieros del año completo 2024 para el 31 de marzo de 2025, a las 4:30 p.m. hora del Este. La presentación incluirá tanto una revisión del rendimiento financiero como actualizaciones de la empresa.
Los participantes pueden unirse por teléfono al (646) 307-1963 (EE. UU.) o al (800) 715-9871 (número gratuito) utilizando el ID de conferencia 9767621. Un webcast en vivo estará disponible a través de la sección de Inversores del sitio web de Daré. La grabación del webcast permanecerá accesible para su repetición hasta el 14 de abril de 2025.
Daré Bioscience (NASDAQ: DARE), 여성 건강 혁신 회사,는 2024 회계연도 전체 재무 결과에 대한 컨퍼런스 콜 및 웹캐스트를 2025년 3월 31일 동부 표준시 오후 4시 30분에 예정했습니다. 발표에는 재무 성과 검토와 회사 업데이트가 포함됩니다.
참여자는 (646) 307-1963 (미국) 또는 (800) 715-9871 (무료 전화)로 전화에 접속하여 회의 ID 9767621을 사용하여 참여할 수 있습니다. Daré 웹사이트의 투자자 섹션을 통해 실시간 웹캐스트가 제공됩니다. 웹캐스트 녹화는 2025년 4월 14일까지 다시 볼 수 있습니다.
Daré Bioscience (NASDAQ: DARE), une entreprise d'innovation en santé féminine, a programmé sa conférence téléphonique et webcast sur les résultats financiers de l'année complète 2024 pour le 31 mars 2025 à 16h30, heure de l'Est. La présentation comprendra à la fois un examen de la performance financière et des mises à jour de l'entreprise.
Les participants peuvent se joindre par téléphone au (646) 307-1963 (États-Unis) ou au (800) 715-9871 (numéro gratuit) en utilisant l'ID de conférence 9767621. Un webcast en direct sera disponible via la section Investisseurs du site web de Daré. L'enregistrement du webcast restera accessible pour rediffusion jusqu'au 14 avril 2025.
Daré Bioscience (NASDAQ: DARE), ein Innovationsunternehmen im Bereich Frauengesundheit, hat seine Konferenzschaltung und Webcast zu den Finanzzahlen des gesamten Jahres 2024 für den 31. März 2025 um 16:30 Uhr Eastern Time angesetzt. Die Präsentation wird sowohl eine Überprüfung der finanziellen Leistung als auch Unternehmensupdates umfassen.
Teilnehmer können sich telefonisch unter (646) 307-1963 (USA) oder (800) 715-9871 (gebührenfrei) mit der Konferenz-ID 9767621 einwählen. Ein Live-Webcast wird im Investorenbereich der Daré-Website verfügbar sein. Die Aufzeichnung des Webcasts bleibt bis zum 14. April 2025 für eine Wiederholung zugänglich.
- None.
- None.
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and well-being of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, March 31, 2025, to review its financial results for the year ended December 31, 2024, and to provide a company update.
To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free). The conference ID number for the call is 9767621. The live webcast can be accessed under “Presentations, Events & Webcasts” in the Investors section of the company's website at http://ir.darebioscience.com. Please log in approximately 5–10 minutes prior to the call to register and to download and install any necessary software. The webcast will be archived in the same section of the company's website and available for replay until April 14, 2025.
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious diseases, and menopause.
The first FDA-approved product to emerge from Daré’s portfolio of women’s health product candidates is XACIATO™ (clindamycin phosphate) vaginal gel
Daré Bioscience leadership has been named on the Medicine Maker’s Power List and Endpoints News’ Women in Biopharma 2022. In 2023, Daré's CEO was honored as one of Fierce Pharma’s Most Influential People in Biopharma for Daré’s contributions to innovation and advocacy in the women’s health space. Daré Bioscience placed #1 in the Small Company category of the San Diego Business Journal’s 2023 Best Places to Work Awards.
Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.
Contacts:
Daré Bioscience Investor Relations
innovations@darebioscience.com
Source: Daré Bioscience, Inc.
